Cancer Treatment Breakthrough: Hoth Therapeutics Shows Promise

HT-001 Treatment Shows Impressive Results

Hoth Therapeutics has shared exciting news from their ongoing cancer trial. The company is testing a treatment called HT-001 on patients who are also taking EGFR inhibitor therapy. The results so far are quite impressive.

• 100% Response Rate: Every patient who could be evaluated showed a positive response by the sixth week.
• Disease Severity Reduced by Half: The severity of their disease was cut by about half.
• Quick and Lasting Effects: Improvements were seen as early as three weeks and lasted through the sixth week.
• Additional Benefits:
• 34% improvement in side effects from cancer treatment.
• 37% reduction in itching, a common problem for these patients.

Other Promising Treatments

Hoth Therapeutics is also working on other treatments. In a separate study, they found that their treatment HT-KIT caused significant tumor cell death in certain types of cancer. This is promising news for the future.

Stock Performance and Analyst Outlook

• Recent Performance: Hoth Therapeutics' stock has been having a tough time lately. It's down about 22.79% over the past year and is closer to its lowest point than its highest.
• Short-Term Hope: The stock is showing bullish momentum in the short term, which means it might be on the way up.
• Analyst Ratings:
• Buy rating with an average price target of $6.50.
• This is higher than the current stock price, so they believe it has room to grow.